Acurx Pharmaceuticals Inc
Company Profile
Business description
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Contact
259 Liberty Avenue
Staten IslandNY10305
USAT: +1 917 533-1469
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
ASX energy giant undervalued despite commissioning challenges
stocks
Undervalued ASX share upgrades guidance
stocks
ASX major bank drives strong quarterly profit
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,112.00 | 79.70 | 0.88% |
| CAC 40 | 8,458.78 | 52.72 | 0.63% |
| DAX 40 | 25,464.01 | 102.98 | 0.41% |
| Dow JONES (US) | 52,878.47 | 668.39 | 1.28% |
| FTSE 100 | 10,871.02 | 89.27 | 0.83% |
| HKSE | 25,310.85 | 103.67 | 0.41% |
| NASDAQ | 24,970.37 | 38.29 | 0.15% |
| Nikkei 225 | 62,364.92 | 2,566.27 | -3.95% |
| NZX 50 Index | 13,861.93 | 11.24 | 0.08% |
| S&P 500 | 7,449.44 | 36.26 | 0.49% |
| S&P/ASX 200 | 8,947.80 | 85.60 | 0.97% |
| SSE Composite Index | 3,813.31 | 44.93 | -1.16% |